← Eichor
Study identifier: NCT06558214 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Condition: Recurrent Glioblastoma  ·  Sponsor: University of Florida

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.

This description comes directly from the study's public registry record.

Talk to the study team

Victoria Hope  ·  352-273-9000  ·  victoria.hope@neurosurgery.ufl.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UF Health Shands HospitalGainesville, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06558214